Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC148 plus chemotherapy versus bevacizumab plus chemotherapy as first-line treatment for unresectable or metastatic colorectal cancer
CTR20260832Phase 3Active
- Sponsor
- RemeGen
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RC148, bevacizumab in colorectal cancer (CRC), sponsored by RemeGen. Started May 2026; status: active.
02
Drugs
RC148bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20260832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260832.